Harrow, Inc.
corporate_fare Company Profile
Harrow, Inc. (NASDAQ:HROW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for HROW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for HROW spans 10-Q, 8-K, 4, 10-K.
Recent high-impact activity:
- Harrow 10-Q: Record Q3 Revenue $99.3M, $9.8M Net Income; VEVYE Licensor Consent Risk on TYRVAYA
- Harrow Q3 Revenue $99.3M but Adjusted EBITDA Guidance Cut to $40M+ from $80-100M
- Harrow Posts 25c Q3 EPS, Swinging to Profit From Prior Loss
- Harrow Closes TYRVAYA Acquisition with Revised Terms: Japan Rights Retained by Viatris, $30M Fixed Cash Consideration
- Iheezo Cuts Eye-Injection Discomfort 58% in Head-to-Head Study
Financial Snapshot
Short Interest & Short Volume
14.13 days to coverFINRA reported short interest of 7,092,437 shares in HROW as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 14.1 days to cover at its recent average daily volume. On November 20, 2026, 60.2% of HROW volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.